Why CGAP?
The Computational Genome Analysis Platform (CGAP) has been imperative in the analyses of the PPM genomic data and identification of variants, allowing researchers to search for potential causal links between phenotypes and specific variants of interest in current and future research efforts.
PPM used CGAP to identify the genetic variants associated with exceptional response to cancer treatments.
About the Project
The PPM NEER (Network of Enigmatic Exceptional Responders) study has focused efforts on collecting data for individuals who have demonstrated an exceptional response to cancer treatments. To date, a wealth of data has been collected on nearly 90 exceptional responders, including medical records, self-reported data through questionnaires, microbiome analyses, immunosequencing and genomics.
Additionally, a new PPM initiative, Rheumatoid Arthritis Non-responders to Treatments (RANT), is also underway, collecting data on individuals with RA who have had poor or no response to biologic therapies. The opportunity to bring together the otherwise isolated cases of exceptional and non-responders will afford fully consolidated repositories of a sufficient number of cases rich with phenotypic, genomic, environmental, and psychosocial information to enable exploratory research on possible commonalities of etiology or expression and will also facilitate the location of other individuals who might have the same commonalities.
